Integrated risk-informed AI-assisted weak signals screening solutions

Reinventing the future with responsible AI, enhanced by multi-scale risk models, to enable multi-year risk prediction, uncertainty quantification, and early detection of weak signals of rare events.

Before a rare event speaks, weak signals whisper

By detecting early weak signals during the incubation of rare events and identifying new predictive risk markers across multi-scale clinical data, raw inputs, and multimodal imaging, HOPE VALLEY AI empowers healthcare providers, public health stakeholders, and clinical researchers to anticipate, assess, and predict rare event risks with quantified uncertainty, capturing the earliest signs of incubation, years before such rare events occur.

40%

of all diagnosed cancer cases are preventable and are associated with avoidable risk factors.

Source : Santé publique France, 2018

40%

of breast cancers occur in women who could have been identified as augmented-risk patients, years prior to diagnosis.

Source : Interception - Gustave Roussy

11%

5-year survival rate of pancreatic cancer all stages combined. It is expected to become the 2nd deadliest cancer in France in 2040.

Source: Prof. Louis de Mestier (AP-HP)

Our first public health initiative

The HOPE Initiative primarily focuses on multi-year breast cancer risk prediction and early detection of weak signals to improve access to prevention and care, particularly in underserved communities.

Building integrated risk-informed AI-assisted solutions to empower patients to “Know their Normal” and help their healthcare providers, clinical researchers and industry to save lives and defeat cancer with integrated multi-scale risk prediction and AI-assisted detection of early weak signals of rare events before they occur.

Early detection of cancer significantly increases the chances of survival while reducing the financial burden on healthcare systems.

Patients diagnosed at stage I benefit from substantially higher 5-year survival rates, up to 99% for breast cancer and 100% for lung cancer, compared to those diagnosed at stage IV, where survival drops to as low as 7%.

Moreover, the average cancer-related healthcare costs within one year of diagnosis escalate sharply with later-stage detection. For instance, treating prostate cancer at stage IV costs over $440,000, compared to $123,000 at stage I.

Similar patterns are seen across other cancer types, with costs multiplying two to six times between early and late-stage diagnoses. These figures underscore the critical importance of early screening and detection programs—not only for saving lives but also for ensuring more sustainable healthcare expenditure.

Our first use case: integrated modular AI solutions to defeat breast cancer through digital prevention, multi-year risk prediction and early detection.

Smart Breast Health e-Clinic on Smartphone (1st module)

The HOPE Application, designed for women over 25, is a breast health companion that offers science-based guidance, insights, and smart tips for regular self-checks. It is not a medical device and does not replace medical advice or a doctor’s consultation.

Integrated AI-assisted Healthcare Platform (2nd module)

The HOPE Platform, designed for healthcare providers, is an AI-assisted medical solution integrating BREASCREEN and BREASCAN medical devices, currently under evaluation, to support clinical decision-making through AI-based remote patient monitoring and 12-month & 5-year risk prediction.

Integrated AI-assisted Ultrasound RF Medical Device (3rd module)

MAMMOPE is a multimodal AI-powered medical device based on Ultrasound RF technology, currently in active R&D, designed to support frontline primary care providers in underserved areas. It complements, but does not replace, the gold standard breast cancer mammography screening program.

This is HOPE, a modular solution for proactive breast self-check monitoring for patients and their care providers.

Breast Cancer is highly curable and it can be successfully treated if detected at an early stage. It can be even avoided through effective breast health education, awareness and prevention.

“Knowing My Normal” is the key component of the breast health awareness which is crucial to breast cancer risk prediction and early detection.

This is the heart of HOPE, the first smart breast health digital clinic on Smartphone, which will be available in October 2025 for all women over 25 and their primary healthcare providers.

MAMMOPE.png

This is MAMMOPE, designed to bring AI-based ultrasound breast health screening to primary care in underserved regions.

MAMMOPE is an innovative AI-based ultrasound medical device, designed by Hope Valley AI with the support of the Design Spot Université Paris-Saclay, to address the issue of medical deserts by empowering primary healthcare providers with a smart non-operator-dependent ultrasound medical device.

It combines multimodal ultrasound with embedded AI to generate real-time, risk-informed breast imaging and a patented 4D digital twin of breast health. This enables continuous tracking of weak signals and offers a safe, radiation-free solution to support routine medical monitoring and preventive screening, used in complement and support of standard methods such as mammography and breast MRI.

This is IRISCREEN, a multi-instance SaaS platform designed to scale across multi-disease applications.

IRISCREEN is a cutting-edge AI-assisted week signals screening platform designed by HOPE VALLEY AI to help researchers and industry partners gain a better understanding of the silent rare events’ incubation challenges, years before they occur.

Powered by integrated multi-scale risk-informed AI-based technology, IRISCREEN integrates multimodal data such as clinical, medical imaging, biological, and genetic data, to characterize new predictive risk markers and early detect weak signals of rare events’ incubation, long before symptoms appear.

Its first deployment in digital oncology targets pancreatic cancer, one of the deadliest cancers with a 5-year survival rate below 11% and a rising incidence in the World.

Proud to be backed by

…and committed business angels, partners and sponsors.

2025 Hope Valley AI. All rights reserved.